Evaluation of Visual Perception Through Diffractive Optical Lens Designs by Virtual Implantation.

Carl Zeiss Meditec AG1 site in 1 country74 target enrollmentMay 10, 2021

ConditionsHealthy

Overview

Evaluation of visual perception through diffractive optical lens designs by virtual implantation.

Registry

clinicaltrials.gov

Start Date

May 10, 2021

End Date

August 19, 2021

Last Updated

4 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Sponsor

Responsible Party

Sponsor

•Male or female subjects between and including 18 and 50 years of age;
•Healthy eyes;
•Dominant eye with a monocular CDVA ≥1.0 decimal (≤ 0.0 logMAR) without cycloplegia;
•Subject who has been informed of the consequences and constraints of the protocol and who has given his/her written informed consent;
•Negative COVID19 screening test prior to every trial visit.

•Subjects of less than 18 or more than 50 years of age;
•Monocular CDVA of dominant eye \< 1.0 decimal (\> 0.0 logMAR) without cycloplegia;
•Subject unable to comply with the study protocol or likely to be non-cooperative during the study;
•Subject whose freedom is impaired by administrative or legal issues, or adult persons under legal protection or unable to give an informed consent;
•Pseudophakic subjects;
•Subjects, who are unable to fixate for a longer time, e.g. strabismus, nystagmus;
•Pathologic miosis;
•Intake of drugs affecting vision;
•Participation in another biomedical study in parallel, if it affects vision or if interactions with cycloplegia exist;
•Intolerance to or contraindication to cycloplegia, e.g. due to narrow angle of the anterior ocular chamber;